Search clinical trials for: AD-209-1B

Total 2933 results

Tampere University Hospital

Completed

Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus | End-Stage Kidney Disease
Galapagos NV

Completed

Oral Bioavailability of Two Solid Formulations of GLPG0634

Healthy

Belgium
Propella Therapeutics

Completed

A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control

Pain | Osteoarthritis, Knee

United States
Juul Labs, Inc.

Completed

Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers

Tobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, Cigarettes

New Zealand
Derming SRL

Completed

Aesthetic Performance of an Intradermal Injection Treatment for Face Photoaging: Interstitial or Cushion Technique in Comparison to Bolus Technique at Five Points (Half - Face Method Within Subjects)

Face Photoaging

Italy
Momotaro-Gene Inc.
Baylor College of Medicine; Synteract, Inc.

Active, not recruiting

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV

HIV

United States
Claudio Gobbi
Bayer

Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Switzerland
Atabay Kimya Sanayi Ticaret A.S.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Completed

Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions (Favipiravir)

Bioequivalence

Turkey
Novelfarma Ilaç San. ve Tic. Ltd. Sti.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Completed

Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions (Favipiravir)

Bioequivalence

Turkey
Sunnybrook Health Sciences Centre

Completed

Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon

Follicular Lymphoma

Canada
Verve Therapeutics, Inc.

Not yet recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Hypercholesterolemia
Zhejiang University

Recruiting

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

Transthyroxin Amyloidosis Cardiomyopathy

China
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Nasopharyngeal Cancer | Epstein-Barr Virus Related Carcinoma

United States
Everfront Biotech Co., Ltd.

Not yet recruiting

A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer

Pancreatic Cancer
Biomea Fusion Inc.

Suspended

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus (BF-MNN-112)

Type 1 Diabetes Mellitus

United States, Canada
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
Vergent Bioscience, Inc.
National Cancer Institute (NCI)

Completed

Phase 2 Study of VGT-309 in Lung Cancer

Lung Cancer

United States
Nanexa AB
CTC Clinical Trial Consultants AB

Completed

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

Multiple Myeloma

Sweden
Hunan Province Tumor Hospital

Completed

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

NSCLC

China
Lumen Bioscience, Inc.

Completed

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

C. Diff. Infections

Australia
Otonomy, Inc.

Completed

Open-Label Study of OTO-201 for Treatment of AOMT

Acute Otitis Media | AOMT

United States
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours (KIDES-203)

Solid Tumours

France, Finland, Spain, Italy, Denmark, United Kingdom
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
RXi Pharmaceuticals, Corp.

Unknown

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Age-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal Fibrosis

United States
Meir Hospital, Kfar Saba, Israel

Unknown

Assessment of Pain in Surgical Patient by PMD 200

Pain, Postoperative
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Finland, France, Czech Republic, Estonia
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Aragon Pharmaceuticals, Inc.

Completed

14C-ARN-509 Microtracer Label AME and Absolute BA Study

Healthy

Netherlands
LivaNova

Completed

Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker (DREAM)

Bradycardia

France, Spain
Sangamo Therapeutics

Completed

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) (ALS)

Amyotrophic Lateral Sclerosis

United States
Taiho Pharmaceutical Co., Ltd.

Terminated

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Lytix Biopharma AS

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

Atopic Dermatitis | Gram-positive, Skin Infections | Mild Eczema/Dermatoses

Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Diabetes Mellitus

China, United States, Canada, Mexico, Russian Federation, Croatia, United Kingdom, Argentina, Australia, India, South Africa, Greece, Ukraine, Romania, Italy, Hong Kong, Former Serbia and Montenegro, Brazil
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

Healthy
Chen Li

Recruiting

Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD

ADHD

China
University of California, Davis
National Heart, Lung, and Blood Institute (NHLBI); University of Southern California and other collaborators

Completed

Adverse Metabolic Effects of Dietary Sugar

Obesity | Type 2 Diabetes | Chronic Disease of Cardiovascular System

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Relapsing Remitting Multiple Sclerosis
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Atsena Therapeutics Inc.

Recruiting

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

X-linked Retinoschisis

United States
Pyxis Oncology, Inc

Recruiting

Study of PYX-201 in Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, Spain, Belgium
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Pyramid Biosciences

Terminated

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Solid Tumor, Adult | Desmoplastic Small Round Cell Tumor | Brain Tumor, Primary

France, United States, Spain, Hong Kong, United Kingdom, Australia, Singapore, Germany, Korea, Republic of, Italy, Denmark
Daxor Corporation
Oregon Health and Science University; Stern Cardiovascular Foundation, Inc.

Completed

BVA-200 vs BVA-100 Validation Study

Heart Failure | Kidney Diseases | Diabetes | Thyroid Diseases | Anemia | Trauma | High Blood Pressure | High Cholesterol | Other Disease | Clotting Disorder

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

Hypercholesterolemia and Hyperlipidemia

China
Coordination Pharmaceuticals, Inc.

Completed

Study of CPI-200 in Patients With Advanced Tumors

Advanced Solid Tumor

United States

Search clinical trials for: AD-209-1B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations